{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T08:19:45Z","timestamp":1777882785463,"version":"3.51.4"},"reference-count":37,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Women's Health Reports"],"published-print":{"date-parts":[[2025,4,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>While the efficacy of brexanolone, a U.S. Food and Drug Administration-approved infusion treatment for postpartum depression (PPD), has been demonstrated in controlled trials, few reports are available describing its real-world effectiveness.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      Leveraging real-world clinical data, the current report describes the characteristics and treatment outcomes of a sample of women (\n                      <jats:italic toggle=\"yes\">N<\/jats:italic>\n                      = 150) receiving brexanolone treatment for PPD in a residential-style outpatient treatment center with up to 12 months of follow-up. The sample had a mean age of 30.0 years (SD = 4.5), with almost one-third (31.3%) on hormonal birth control, and most (91.3%) were taking concomitant psychiatric medications.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Participants reported significant decreases in depression and anxiety symptoms from pretreatment to posttreatment that were sustained across a 12-month follow-up. Edinburgh postnatal depression scale (EPDS) scores decreased from pretreatment (\n                      <jats:italic toggle=\"yes\">M<\/jats:italic>\n                      = 19.9, SD = 4.1) to posttreatment (\n                      <jats:italic toggle=\"yes\">M<\/jats:italic>\n                      = 10.5, SD = 4.5,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      &lt; 0.001, within-group effect size [Cohen\u2019s d] of 2.2). At 12 months follow-up, EPDS scores remained significantly lower among the retained subset of patients (\n                      <jats:italic toggle=\"yes\">N<\/jats:italic>\n                      = 64,\n                      <jats:italic toggle=\"yes\">M<\/jats:italic>\n                      = 9.2, SD = 6.5). Among a subset who underwent formal assessments for anxiety, scores on the perinatal anxiety screening scale decreased from pretreatment (\n                      <jats:italic toggle=\"yes\">M<\/jats:italic>\n                      = 60.1, SD = 17.1) to posttreatment (\n                      <jats:italic toggle=\"yes\">M<\/jats:italic>\n                      = 33.3, SD = 22.1,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      &lt; 0.01, within-group effect size of 1.4). Response and remission rates for depression were 68.7% and 46.7%, respectively, posttreatment, and 73.4% and 60.9%, respectively, at 12-month follow-up. Importantly, 15 participants had a diagnosis of bipolar depression and were prescribed an antipsychotic or mood stabilizer at the time of treatment, there were no episodes of mania or hypomania reported during the follow-up period.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Given the shared mechanism of action between brexanolone and the recently approved oral medication for PPD, zuranolone, the applicability of findings and relevance to the more accessible oral drug, zuranolone, are explored.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/26884844251383702","type":"journal-article","created":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T16:25:57Z","timestamp":1759767957000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Real-World Outcomes of Brexanolone to Treat Postpartum Depression"],"prefix":"10.1177","volume":"6","author":[{"given":"Melanie","family":"Barrett","sequence":"first","affiliation":[{"name":"LifeStance Health, Scottsdale, Arizona, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Hettema","sequence":"additional","affiliation":[{"name":"LifeStance Health, Scottsdale, Arizona, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Constance","family":"Youngman","sequence":"additional","affiliation":[{"name":"LifeStance Health, Scottsdale, Arizona, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel T.","family":"Wilkinson","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, School of Medicine, Yale University, New Haven, Connecticut, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel","family":"Dalthorp","sequence":"additional","affiliation":[{"name":"LifeStance Health, Scottsdale, Arizona, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2026,3,19]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890425596"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0000000000002927"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-021-01663-6"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/da.22597"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-020-03017-w"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.4305"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.50897"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1177\/1745506519844044"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.2105\/ajph.2020.305619"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.4088\/jcp.15r10174"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2022.09.143"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2018-3259"},{"key":"e_1_3_2_14_2","unstructured":"U.S. Preventative Services Taskforce. Interventions to Prevent Perinatal Depression; 2019. Available from: https:\/\/www.uspreventiveservicestaskforce.org\/uspstf\/recommendation\/perinatal-depression-preventive-interventions [Last accessed: November25 2024]."},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.cd006116.pub2"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-023-04547-9"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-019-00605-7"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijgo.15980"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.65866"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(17)31264-3"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(18)31551-4"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaclp.2021.08.001"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41386-023-01721-1"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00737-020-01042-y"},{"key":"e_1_3_2_25_2","volume-title":"Hamilton Rating Scale for Depression (HRSD, HAM-D) [Database record].","author":"Hamilton M","year":"1960","unstructured":"Hamilton M. Hamilton Rating Scale for Depression (HRSD, HAM-D) [Database record]. APA PsycTests; 1960."},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.166.10.1092"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852900025815"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00737-014-0425-8"},{"key":"e_1_3_2_29_2","volume-title":"Perinatal Anxiety Screening Scale (PASS) [Database record].","author":"Somerville S","year":"2014","unstructured":"Somerville S, , Dedman K, , Hagan R, et al. Perinatal Anxiety Screening Scale (PASS) [Database record]. APA PsycTests; 2014."},{"key":"e_1_3_2_30_2","volume-title":"Yale-Brown Obsessive Compulsive Scale (YBOCS) [Database record].","author":"Goodman WK","year":"1989","unstructured":"Goodman WK, , Price LH, , Rasmussen SA, et al. Yale-Brown Obsessive Compulsive Scale (YBOCS) [Database record]. APA PsycTests; 1989."},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.12m07789"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.4300\/JGME-D-12-00156.1"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41386-024-01818-1"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2021.1559"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.20220785"},{"key":"e_1_3_2_36_2","unstructured":"Title: Real-World Experience with Brexanolone Injection for Intravenous (IV) Use to Treat Postpartum Depression: Patient Characteristics and Results from a Maternal Mental Health Treatment Center."},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1991.01810330075011"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2022.873693"}],"container-title":["Women's Health Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/26884844251383702","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/26884844251383702","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/26884844251383702","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T01:23:21Z","timestamp":1777598601000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/26884844251383702"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,1]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,4,1]]}},"alternative-id":["10.1177\/26884844251383702"],"URL":"https:\/\/doi.org\/10.1177\/26884844251383702","relation":{},"ISSN":["2688-4844","2688-4844"],"issn-type":[{"value":"2688-4844","type":"print"},{"value":"2688-4844","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,1]]},"article-number":"26884844251383702"}}